Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19282209 | 0.87 | KMT2A (0.52) | RAB9AMEN1KMT2ASCN9AMPO | |
| SCHEMBL19294221 | 0.87 | NPC1 (0.50) | RAB9ASCN9AMPONPC1SMN1; SMN2 | |
| SCHEMBL19282260 | 0.86 | NPC1 (0.43) | RAB9AMEN1KMT2AMPOALDH1A1 | |
| SCHEMBL19282224 | 0.82 | MPO (0.67) | RAB9AMEN1KMT2ASCN9AMPO | |
| SCHEMBL20429915 | 0.82 | MPO (0.46) | MPO | |
| SCHEMBL20429882 | 0.82 | SMN1; SMN2 (0.46) | KMT2AMPOALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL19282278 | 0.81 | SCN9A (0.54) | SCN9AMPOTP53 | |
| SCHEMBL19294227 | 0.80 | MPO (0.66) | RAB9AMPO | |
| SCHEMBL20429877 | 0.79 | MPO (0.51) | RAB9AMEN1KMT2AMPOALDH1A1 | |
| SCHEMBL20429890 | 0.79 | MPO (0.50) | MPOALDH1A1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | RAB9A 4260/4885MEN1 4776/4885KMT2A 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.